EnliTISA Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 6

EnliTISA General Information

Description

Manufacturer of pharmaceuticals intended to develop effective therapies for inflammatory and fibrotic diseases. The company offers advanced drug research, clinical-stage development, and patented compounds, enabling healthcare providers to address unmet medical needs with safer and better-tolerated treatments.

Contact Information

Formerly Known As
Berison (Shanghai) Pharmaceutical
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Rooms 201, 202, 203, BuildingA
  • Block1, Number 800, Qingdai Road, Pudong New District, Shanghai
  • Shanghai, 201318
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Corporate Office
  • Rooms 201, 202, 203, BuildingA
  • Block1, Number 800, Qingdai Road, Pudong New District, Shanghai
  • Shanghai, 201318
  • China
+86 021

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EnliTISA Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Early Stage VC 26-Sep-2024 Completed Generating Revenue
8. Early Stage VC 21-Jun-2024 Completed Generating Revenue
7. Early Stage VC (Series A1) 03-Mar-2024 Completed Generating Revenue
6. Secondary Transaction - Private 31-Mar-2024 Completed Generating Revenue
5. Early Stage VC 19-Sep-2023 Completed Generating Revenue
4. Secondary Transaction - Private 28-Jul-2023 Completed Generating Revenue
3. Secondary Transaction - Private 29-May-2023 Completed Generating Revenue
2. Early Stage VC 29-Sep-2022 Completed Generating Revenue
1. Secondary Transaction - Private 22-Jul-2022 Completed Generating Revenue
To view EnliTISA’s complete valuation and funding history, request access »

EnliTISA Patents

EnliTISA Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025195444-A1 New use of peptides derived from vasoactive intestinal peptide Pending 20-Mar-2024
EP-4798158-A1 New short-chain peptides and derivatives thereof Pending 23-Oct-2023
WO-2025087269-A1 New short-chain peptides and derivatives thereof Inactive 23-Oct-2023
AU-2024312518-A1 New multi-functional oligopeptides Pending 22-Jun-2023
EP-4731305-A1 New multi-functional oligopeptides Pending 22-Jun-2023 C07K7/06
To view EnliTISA’s complete patent history, request access »

EnliTISA Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Sunbow Capital Asset Manager Minority
CAS Investment Management Growth/Expansion Minority
Step Holdings Venture Capital Minority
StepVC Venture Capital Minority
Zhangjiang Hi-Tech Park Corporation Minority
You’re viewing 5 of 6 investors. Get the full list »

EnliTISA FAQs

  • When was EnliTISA founded?

    EnliTISA was founded in 2021.

  • Where is EnliTISA headquartered?

    EnliTISA is headquartered in Shanghai, China.

  • What industry is EnliTISA in?

    EnliTISA’s primary industry is Drug Discovery.

  • Is EnliTISA a private or public company?

    EnliTISA is a Private company.

  • What is EnliTISA’s current revenue?

    The current revenue for EnliTISA is .

  • Who are EnliTISA’s investors?

    Sunbow Capital, CAS Investment Management, Step Holdings, StepVC, and Zhangjiang Hi-Tech Park are 5 of 6 investors who have invested in EnliTISA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process